36881-42-2

Basic information

• Product Name: 1-(BROMOMETHYL)-4-PHENOXYBENZENE
• Synonyms: 1-(BROMOMETHYL)-4-PHENOXYBENZENE;4-PHENYLOXYBENZYLBROMIDE;4-Phenoxybenzyl bromide 97%;4-Phenoxybenzyl bromide;Benzene, 1-(bromomethyl)-4-phenoxy-;1-broMethyl-4-phenoxybenzene;4-Phenoxybenzylbromide97%
• CAS NO: 36881-42-2
• Molecular Formula: C₁₃H₁₁BrO
• Molecular Weight: 263.13
• EINECS: 253-253-6
• Product Categories: pharmacetical
• Mol File: 36881-42-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 328.3 °C at 760 mmHg
• Flash Point: 129.2 °C
• Appearance: /
• Density: 1.388 g/cm³
• Vapor Pressure: 0.000366mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Lachrymatory
• CAS DataBase Reference: 1-(BROMOMETHYL)-4-PHENOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(BROMOMETHYL)-4-PHENOXYBENZENE(36881-42-2)
• EPA Substance Registry System: 1-(BROMOMETHYL)-4-PHENOXYBENZENE(36881-42-2)

Safety Data

• Hazard Codes: C
• Statements: 43
• Safety Statements: 36/37
• HazardClass: 8
• Hazardous Substances Data: 36881-42-2(Hazardous Substances Data)

Usage

Description

1-(Bromomethyl)-4-phenoxybenzene is an organic compound characterized by its bromine atom attached to a benzene ring, which is connected to a phenoxy group. This chemical structure grants it unique properties and potential applications in various fields.

Uses

1. Used in Pharmaceutical Industry:
1-(Bromomethyl)-4-phenoxybenzene is used as a chemical intermediate for the synthesis of indole derivatives. These derivatives serve as matriptase 2 inhibitors, which are crucial in the treatment of various diseases. The inhibition of matriptase 2 can help regulate biological processes and provide therapeutic benefits for patients.
2. Used in Chemical Synthesis:
1-(Bromomethyl)-4-phenoxybenzene can be utilized as a building block in the synthesis of more complex organic molecules. Its unique structure allows for further functionalization and modification, making it a valuable component in the development of new compounds with potential applications in various industries.
3. Used in Research and Development:
In academic and industrial research settings, 1-(Bromomethyl)-4-phenoxybenzene can be employed as a starting material or a reagent in the exploration of new chemical reactions and the development of novel synthetic pathways. Its unique properties may lead to the discovery of new compounds with interesting applications in various fields, such as materials science, pharmaceuticals, and agrochemicals.

InChI:InChI=1/C13H11BrO/c14-10-11-6-8-13(9-7-11)15-12-4-2-1-3-5-12/h1-9H,10H2

Upstream product

• 50-00-0 formaldehyd 
• 101-84-8 diphenylether 
• 1706-12-3 4-phenoxytoluene 
• 2215-78-3 (4-phenoxyphenyl)methanol 
• 2215-77-2 4-Phenoxybenzoic acid 
• 67-36-7 4-phenoxy benzaldehyde 

Downstream Products

• 67-36-7 4-phenoxy benzaldehyde 
• 107622-80-0 4-phenoxybenzylamine 
• 1027728-15-9 1,1-Dioxo-2-(4-phenoxy-benzyl)-1,2-dihydro-1λ⁶-benzo[d]isothiazol-3-one 
• 139259-73-7 p-phenoxybenzyl benzohydroxamate 
• 1025941-48-3 Decanethioic acid S-[(S)-1-hydroxymethyl-2-(4-phenoxy-benzyloxy)-ethyl] ester 
• 1026905-97-4 (S)-1-[(4-Methoxy-phenyl)-diphenyl-methoxy]-3-(4-phenoxy-benzyloxy)-propan-2-ol 
• 1027074-71-0 (R)-1-[(4-Methoxy-phenyl)-diphenyl-methoxy]-3-(4-phenoxy-benzyloxy)-propane-2-thiol 
• 1026331-73-6 Decanethioic acid S-[(R)-2-(dimethoxy-phosphoryloxy)-1-(4-phenoxy-benzyloxymethyl)-ethyl] ester 
• 1026901-94-9 Thioacetic acid S-[(R)-2-[(4-methoxy-phenyl)-diphenyl-methoxy]-1-(4-phenoxy-benzyloxymethyl)-ethyl] ester 
• 1026013-09-1 Toluene-4-sulfonic acid (S)-2-[(4-methoxy-phenyl)-diphenyl-methoxy]-1-(4-phenoxy-benzyloxymethyl)-ethyl ester 
• 161392-14-9 Decanethioic acid S-[(R)-2-[(4-methoxy-phenyl)-diphenyl-methoxy]-1-(4-phenoxy-benzyloxymethyl)-ethyl] ester 

Relevant articles and documents

Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists

Aim: Retinoic acid receptor-related orphan nuclear receptors (RORs) are orphan nuclear receptors that show constitutive activity in the absence of ligands. Among 3 subtypes of RORs, RORc is a promising therapeutic target for the treatment of Th17-mediated autoimmune diseases. Here, we report novel RORc inverse agonists discovered through structure-based drug design. Methods: Based on the structure of compound 8, a previously described agonist of RORa, a series of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives were designed and synthesized. The interaction between the compounds and RORc was detected at molecular level using AlphaScreen assay. The compounds were further examined in 293T cells transfected with RORc and luciferase reporter gene. Thermal stability shift assay was used to evaluate the effects of the compounds on protein stability. Results: A total of 27 derivatives were designed and synthesized. Among them, the compound 22b was identified as the most potent RORc inverse agonist. Its IC50 values were 2.39 μmol/L in AlphaScreen assay, and 0.82 μmol/L in inhibition of the cell-based luciferase reporter activity. Furthermore, the compound 22b displayed a 120-fold selectivity for RORc over other nuclear receptors. Moreover, a molecular docking study showed that the structure-activity relationship was consistent with the binding mode of compound 22b in RORc. Conclusion: 4-(4-(Benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-one derivatives are promising candidates for the treatment of Th17-mediated autoimmune diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.

Synthesis and structure-activity analysis of new phosphonium salts with potent activity against African trypanosomes

A series of 73 bisphosphonium salts and 10 monophosphonium salt derivatives were synthesized and tested in vitro against several wild type and resistant lines of Trypanosoma brucei (T. b. rhodesiense STIB900, T. b. brucei strain 427, TbAT1-KO, and TbB48). More than half of the compounds tested showed a submicromolar EC50 against these parasites. The compounds did not display any cross-resistance to existing diamidine therapies, such as pentamidine. In most cases, the compounds displayed a good selectivity index versus human cell lines. None of the known T. b. brucei drug transporters were required for trypanocidal activity, although some of the bisphosphonium compounds inhibited the low affinity pentamidine transporter. It was found that phosphonium drugs act slowly to clear a trypanosome population but that only a short exposure time is needed for irreversible damage to the cells. A comparative molecular field analysis model (CoMFA) was generated to gain insights into the SAR of this class of compounds, identifying key features for trypanocidal activity.

Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARα and PPARγ agonist activity

PPARs are ligand-activated transcription factors that govern lipid and glucose homeostasis and play a central role in cardiovascular disease, obesity, and diabetes. Herein, we present screening results for a series of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives, some of which are potent PPARγ agonists as well as PPARα agonists. To investigate the binding modes of the most interesting derivatives into the PPARα and PPARγ binding clefts and evaluate their agonist activity, docking experiments, molecular dynamics simulations, and MM-PBSA analysis were performed.